Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.64 |
| ▸ | EBP | Q15125 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7318786 | 1.00 | SIGMAR1 (0.64) | SIGMAR1TMEM97EBPKDM4ECNR2 | |
| SCHEMBL7318794 | 1.00 | SIGMAR1 (0.64) | SIGMAR1TMEM97EBPKDM4ECNR2 | |
| SCHEMBL7318790 | 1.00 | SIGMAR1 (0.64) | SIGMAR1TMEM97EBPKDM4ECNR2 | |
| SCHEMBL11634254 | 0.81 | SIGMAR1 (0.76) | SIGMAR1TMEM97EBPKDM4E | |
| SCHEMBL29412726 | 0.81 | SIGMAR1 (0.76) | SIGMAR1TMEM97EBPKDM4E | |
| SCHEMBL8328268 | 0.81 | SIGMAR1 (0.76) | SIGMAR1TMEM97EBPKDM4E | |
| Hydrochloric Acid SCHEMBL30570019 | 0.80 | SIGMAR1 (0.74) | SIGMAR1TMEM97EBPKDM4E | |
| SCHEMBL11631505 | 0.78 | SIGMAR1 (0.72) | SIGMAR1TMEM97EBPKDM4E | |
| SCHEMBL11633441 | 0.78 | SIGMAR1 (0.72) | SIGMAR1TMEM97EBPKDM4E | |
| SCHEMBL29412724 | 0.78 | SIGMAR1 (1.00) | SIGMAR1TMEM97EBPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | MELETIOS THERAPEUTICS (FR) | 2023-11-16 | — | — | US | disclosed |
| EP-4213822-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | MELETIOS Therapeutics (FR) | 2023-07-26 | — | — | EP | disclosed |
| US-6235791-B1 | USING CIS N-CYCLOHEXYL-N-ETHYL(3-(3-CHLORO-CYCLOHEXYLPHENYL)ALLYL)AMINE | SANOFI-SYNTHELABO (FR) | 2001-05-22 | — | — | US | disclosed |
| EP-0917464-A1 | USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION | SANOFI (FR) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998004251-A1 | USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION | SANOFI (FR) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | ACE, HAVCR2, FURIN | SIGMAR1 3429/4885TMEM97 3055/4885EBP 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.